Please login to the form below

Not currently logged in
Email:
Password:

Multiple approvals for Novartis' MS drug

Novartis has received approval in Switzerland and Australia for its MS drug Gilenya, and a recommendation from CHMP for its use in the EU

Novartis has received approval from Swissmedic, the Swiss Agency for therapeutic products, and the Australian Therapeutic Goods Administration (TGA) for Gilenya (fingolimod) 0.5 mg as a first-line, oral disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis (RRMS).

The Committee for Medicinal Products for Human Use (CHMP), an expert committee of the European Medicines Agency (EMA), has adopted a positive opinion and recommended the approval of Gilenya 0.5 mg. A UK licence is expected in the next few months.

Gilenya is already approved in the US and Russia and has been filed with health authorities worldwide.

"MS is an unpredictable condition. People with MS live with the uncertainty of not knowing when a relapse will next strike; causing distress and affecting work and family life. Some people recover from the relapses, others do not, which contributes to disability." said Dr Eli Silber, fingolimod clinical trial investigator and consultant neurologist who leads an MS service for South London based at King's College.  

The Gilenya approvals and CHMP opinion were based on data from a large clinical trial programme showing that Gilenya reduced relapses by 52 per cent at one year when compared with interferon beta-1a IM, an approved first-line DMT. The data also showed a 54 per cent reduction in relapses at two years compared with placebo.

The trial data also showed that patients receiving Gilenya had a 30 per cent lower risk of disability progression, confirmed after three months and a 37 per cent lower risk of disability progression, confirmed after six months. Gilenya has a well-studied safety and tolerability profile and has been tested on more than 4,000 clinical trial patients worldwide.

Gilenya works differently to any other MS treatment by controlling immune cells that mistakenly attack the brain and spinal cord. These cells (lymphocytes) are retained in the lymph nodes (glands) to prevent them from causing damage. 

MS affects around 100,000 people in the UK and around 2.5m people globally. It is typically diagnosed between 20-40 years of age, with women twice as likely to develop the condition than men. MS is potentially the most common cause of non-traumatic, neurological disability in young adults.

24th January 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics